Drug Type Small molecule drug |
Synonyms Harmine, harmine, 去氢骆驼蓬碱 + [2] |
Target |
Action modulators |
Mechanism MAO-A modulators(Monoamine oxidase A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC13H12N2O |
InChIKeyBXNJHAXVSOCGBA-UHFFFAOYSA-N |
CAS Registry442-51-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognition | Phase 3 | Switzerland | 01 Dec 2020 | |
Depressive Disorder | Phase 3 | Switzerland | 01 Dec 2020 | |
Diabetes Mellitus, Type 1 | Preclinical | United States | 09 Mar 2015 | |
Diabetes Mellitus, Type 2 | Preclinical | United States | 09 Mar 2015 |
Phase 1 | 27 | (Harmine Hydrochloride 100mg) | cxqcorezch(gyzhpmnlim) = qvuxhdfzpd rfssbhvsbb (aonzvmuwte, cchzesmxow - svgqzxqabz) View more | - | 16 Jan 2025 | ||
(Harmine Hydrochloride 200mg) | cxqcorezch(gyzhpmnlim) = btzpqztnyd rfssbhvsbb (aonzvmuwte, lztjiftyhs - orldchvval) View more | ||||||
Not Applicable | - | - | vxtfyrsglm(srdopuwjdm) = increases 2-to-3-fold zssbskabum (dnszgjfvwh ) View more | - | 01 Jun 2022 |